UNSPSC 51313402: Acrivastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A20F9XAI7W, chemically known as 2-propenoic acid, 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-, (e,e)- but generally known as acrivastine, which bears US NIH Compound Identifier 5284514. European Medicines Agency schedules Acrivastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05252MIG.

UNSPSC 51313402 Acrivastine is a Commodity code that captures pharmaceutical products, though recent state and local activity shows the code is being used for a broader range of drug procurement including naloxone, generic pharmaceuticals, and over-the-counter products rather than acrivastine specifically. State and local governments buy under this code through health departments, cooperative purchasing alliances, and county health agencies seeking to stock emergency medications, community health supplies, and pharmacy benefit products. The solicitations indicate procurement offices are sourcing finished pharmaceutical products with specific NDC codes, dosage forms, and manufacturing certifications for distribution to public health facilities and through state employee benefit programs.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing arrangements. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to work through authorized wholesalers and comply with cGMP and drug supply chain security certification. These procurements emphasize pricing competitiveness, compliance with FDA and manufacturing standards, and ability to deliver through established wholesale distribution networks.